Humanigen logo
Humanigen HGEN

Quarterly report 2023-Q1
added 05-15-2023

report update icon

Humanigen Cash Flow 2011-2026 | HGEN

Annual Cash Flow Humanigen

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-76.7 M -184 M -69.9 M -4 M -6.21 M -14.2 M -21 M -29.1 M -35.9 M -38.8 M -23.9 M -15.3 M

Depreciation & Amortization

- - - - 19 K 48 K 102 K 197 K 310 K 298 K 193 K 484 K

Accounts Payables

40.5 M 44.7 M 13.1 M 5.05 M 2.86 M 3.33 M 4.07 M - 1.82 M 3.2 M 2.45 M -

Accounts Receivables

- - - - - - - - - 44 K - -

All numbers in USD currency

Quarterly Cash Flow Humanigen

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-7.06 M - -62.1 M -44.8 M -19.4 M - -152 M -104 M -35.8 M - -46.2 M -22.6 M -607 K - -3.45 M -2.27 M -684 K - -4.98 M -3.73 M -1.83 M - -12.3 M -8.3 M -4.36 M - -17.9 M - -2 M - -21.1 M -14.9 M -9.02 M - -29.1 M -20.7 M -11.3 M - -28.7 M -20.4 M -7.8 M - -15.3 M -8.74 M -3.45 M - -10.7 M -10.1 M -

Depreciation & Amortization

- - - - - - - - - - - - - - - - - - 19 K 19 K 10 K - 38 K 27 K 14 K - 81 K 58 K 33 K - 144 K 91 K 48 K - 254 K 230 K 101 K - 190 K 85 K 42 K - 147 K 104 K 57 K - 413 K 333 K -

Accounts Payables

38.4 M 40.5 M 53.3 M 56.7 M 47.9 M 44.7 M 46 M 37.2 M 43.4 M 15.4 M 15.4 M 15.4 M 15.4 M 5.05 M 5.05 M 5.05 M 5.05 M 2.86 M 2.86 M 2.86 M 2.86 M 3.33 M 3.33 M 3.33 M 3.33 M 4.07 M 4.07 M 4.07 M 4.07 M - 1.02 M 1.33 M 857 K 1.82 M 1.82 M 1.82 M 1.82 M 3.2 M 3.2 M 3.2 M 3.2 M 2.45 M 2.45 M 2.45 M 2.45 M 266 K 266 K 266 K -

Accounts Receivables

- - - 100 K - - - - 5.01 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - 44 K - - - 87 K - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Humanigen, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.56 2.13 % $ 3.74 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
argenx SE argenx SE
ARGX
$ 785.07 2.57 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.43 3.62 % $ 368 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 327.25 2.42 % $ 42.9 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.9 3.7 % $ 9.38 B australiaAustralia
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.49 9.56 % $ 397 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.4 -0.87 % $ 954 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.18 1.21 % $ 447 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.66 3.5 % $ 16.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.61 5.76 % $ 3.13 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.09 0.65 % $ 310 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.41 3.38 % $ 2.15 B usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.88 2.11 % $ 261 B britainBritain